Comment
. 2009 May;20(5):966-7; author reply 967.
doi: 10.1093/annonc/mdp201.
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
- PMID: 19403939
- DOI: 10.1093/annonc/mdp201
Item in Clipboard
Comment
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
Ann Oncol.
2009 May.
Free article
No abstract available
Comment on
-
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.Ann Oncol. 2009 Feb;20(2):393-4. doi: 10.1093/annonc/mdn729. Ann Oncol. 2009. PMID: 19211503 No abstract available.
Similar articles
-
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.Ann Oncol. 2008 Nov;19(11):1975. doi: 10.1093/annonc/mdn566. Epub 2008 Aug 22. Ann Oncol. 2008. PMID: 18723549 No abstract available.
-
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].Bull Cancer. 2008 Sep;95(9):813-20. doi: 10.1684/bdc.2008.0705. Bull Cancer. 2008. PMID: 18829413 French.
-
[Angiogenesis and renal cell carcinoma].Bull Cancer. 2007 Jul;94 Spec No:S232-40. Bull Cancer. 2007. PMID: 17846009 Review. French.
-
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.Clin Transl Oncol. 2010 Aug;12(8):562-7. doi: 10.1007/s12094-010-0554-0. Clin Transl Oncol. 2010. PMID: 20709657
-
Progress in the management of advanced renal cell carcinoma (RCC).Aktuelle Urol. 2010 Jan;41 Suppl 1:S57-60. doi: 10.1055/s-0030-1247237. Epub 2010 Jan 21. Aktuelle Urol. 2010. PMID: 20094957 Review.
Cited by
-
Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function.Hypertension. 2017 Jul 24:HYPERTENSIONAHA.117.09275. doi: 10.1161/HYPERTENSIONAHA.117.09275. Online ahead of print. Hypertension. 2017. PMID: 28739979 Free PMC article.
-
Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.Clin Pharmacokinet. 2015 Apr;54(4):397-407. doi: 10.1007/s40262-014-0207-5. Clin Pharmacokinet. 2015. PMID: 25343945 Clinical Trial.
-
Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).Clin Transl Oncol. 2012 Aug;14(8):564-74. doi: 10.1007/s12094-012-0842-y. Epub 2012 Jul 18. Clin Transl Oncol. 2012. PMID: 22855137
-
Axitinib: in advanced, treatment-experienced renal cell carcinoma.Drugs. 2012 Dec 24;72(18):2375-84. doi: 10.2165/11209230-000000000-00000. Drugs. 2012. PMID: 23190347
-
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.BMC Cancer. 2012 Mar 22;12:107. doi: 10.1186/1471-2407-12-107. BMC Cancer. 2012. PMID: 22439647 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
